A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone

• Drug: erlotinib
  
  erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
• Drug: sunitinib
  
  Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
  Other Name: Sutent
• Drug: placebo
  
  Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity

• Experimental: A
  
  Interventions:
  

  • Drug: erlotinib
  • Drug: sunitinib
• Active Comparator: B
  
  Interventions:
  

  • Drug: erlotinib
  • Drug: placebo

Inclusion Criteria:

• Patients with locally advanced/metastatic non-small cell lung cancer
• Prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen

Exclusion Criteria:

• Prior treatment with any receptor tyrosine kinase inhibitors, Vascular endothelial growth factor (VEGF) inhibitors or other angiogenic inhibitors
• History of or known brain metastases